N-(4,6-dimethyl-1H-benzoimidazol-2-yl)-(3-morpholin-4-yl-propyl)-amine | 857070-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-(4,6-dimethyl-1H-benzoimidazol-2-yl)-(3-morpholin-4-yl-propyl)-amine
• 英文别名: 4,6-dimethyl-N-(3-morpholin-4-ylpropyl)-1H-benzimidazol-2-amine
• CAS: 857070-90-7
• 化学式: C₁₆H₂₄N₄O
• 分子量: 288.393
• InChiKey: ZSUIPSIQAUCBAO-UHFFFAOYSA-N

物化性质

• 沸点：
  485.5±55.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  53.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4,6-dimethyl-1H-benzoimidazol-2-yl)-(3-morpholin-4-yl-propyl)-amine 、 2-(氯甲基)-6-甲基吡啶-3-醇盐酸盐 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以0.1 g的产率得到2-[4,6-dimethyl-2-(3-morpholin-4-yl-propylamino)-benzoimidazol-1-yl-methyl]-6-methyl-pyridin-3-ol
  参考文献：
  名称：

  Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1:  Improving the Pharmacokinetic Profile Using the Structure−Property Relationship

  摘要：

  We previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus (Andries, K.; et al. Antiviral Res. 2003, 60, 209-219). A lead compound of the series was selected for preclinical evaluation. This drug candidate, JNJ-2408068 (formerly R 17059 1, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. We herein describe the optimization program to develop compounds with improved properties in terms of tissue retention. We have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. We have investigated the replacement or the modification of this group, and we suggest that the pK(a) of this part of the molecules influences both the antiviral activity and the pharmacokinetic profile. We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.

  DOI：

  10.1021/jm070143x
• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 、 2-chloro-4,6-dimethyl-1H-benzoimidazole 反应 4.0h， 以68%的产率得到N-(4,6-dimethyl-1H-benzoimidazol-2-yl)-(3-morpholin-4-yl-propyl)-amine
  参考文献：
  名称：

  [EN] MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  [FR] BENZIMIDAZOLES CONTENANT DU MORPHOLINYLE EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS RESPIRATOIRE SYNCYTIAL

  摘要：

  本发明涉及含有对呼吸道合胞病毒复制具有抑制活性的吗啉基苯并咪唑的化合物，其具有式（I），一种前药、N-氧化物、加合盐、季铵盐、金属配合物或其立体化异构体，其中G是直键或可选择地取代的C1-10烷二基；R1是Ar1或单环或双环杂环；Q是R7，R7取代的吡咯烷基、R7取代的哌啶基或R7取代的同构异哌啶基；R2a和R3a中的一个选自卤素、可选择单取代或多取代的Cl-6烷基、可选择单取代或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4)、N(R4aR4)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2Cl-6烷氧基、羧基、Cl-6烷氧羰基或-C(=Z)Ar2；R2a和R3a中的另一个是氢；如果R2a与氢不同，则R2b是氢、C1-6烷基或卤素，R3b是氢；如果R3a与氢不同，则R3b是氢、C1-6烷基或卤素，R2b是氢。还涉及其制备以及包含这些化合物的组合物，以及其作为药物的用途。

  公开号：

  WO2005058871A1

文献信息

• MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  申请人：Bonfanti Jean-Francois

  公开号：US20080280881A1

  公开（公告）日：2008-11-13

  The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 ; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(=Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

  本发明涉及含有吗啡啉基的苯并咪唑，具有对呼吸道合胞病毒复制的抑制活性，其具有以下式子: 其中G为直接键或可选取代的C1-10烷二基；R1为Ar1或单环或双环杂环；Q为R7、用R7取代的吡咯烷基、用R7取代的哌啶基或用R7取代的同型哌啶基；R2a和R3a中的一个选自卤素、可选单或多取代的C1-6烷基、可选单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或—C(=Z)Ar2；而R2a和R3a中的另一个为氢；若R2a不为氢，则R2b为氢、C1-6烷基或卤素，而R3b为氢；若R3a不为氢，则R3b为氢、C1-6烷基或卤素，而R2b为氢。 此外，本发明还涉及其制备方法和包含这些化合物的组合物，以及其作为药物的用途。
• Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
  申请人：Bonfanti Jean-Francois

  公开号：US20070043022A1

  公开（公告）日：2007-02-22

  The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 ; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ) N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(=Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

  本发明涉及含有morpholinyl的苯并咪唑类化合物，具有抑制呼吸道合胞病毒复制的活性，其具有以下式子：a prodrug，N-oxide，加合盐，季铵盐，金属络合物或其立体化学异构体形式，其中G是直链键或可选取代的C1-10烷二基；R1是Ar1或单环或双环杂环；Q是R7，用R7取代的吡咯烷基，用R7取代的哌啶基或用R7取代的同源哌啶基；R2a和R3a中的一个选自卤素，可选取代的C1-6烷基，可选取代的C2-6烯基，硝基，羟基，Ar2，N（R4aR4b），N（R4aR4b）磺酰基，N（R4aR4b）羰基，C1-6烷氧基，Ar2氧基，Ar2C1-6烷氧基，羧基，C1-6烷氧羰基或-C（=Z）Ar2；R2a和R3a中的另一个是氢；如果R2a与氢不同，则R2b是氢，C1-6烷基或卤素，而R3b是氢；如果R3a与氢不同，则R3b是氢，C1-6烷基或卤素，而R2b是氢。本发明进一步涉及其制备方法和包含这些化合物的组合物，以及将其用作药物的用途。
• US7449463B2
  申请人：——

  公开号：US7449463B2

  公开（公告）日：2008-11-11
• US8883837B2
  申请人：——

  公开号：US8883837B2

  公开（公告）日：2014-11-11
• Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1:  Improving the Pharmacokinetic Profile Using the Structure−Property Relationship
  作者：Jean-François Bonfanti、Frédéric Doublet、Jérôme Fortin、Jean Lacrampe、Jérôme Guillemont、Philippe Muller、Laurence Queguiner、Eric Arnoult、Tom Gevers、Peggy Janssens、Heidi Szel、Rudy Willebrords、Philip Timmerman、Koen Wuyts、Frans Janssens、Cois Sommen、Piet Wigerinck、Koen Andries

  DOI：10.1021/jm070143x

  日期：2007.9.1

  We previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus (Andries, K.; et al. Antiviral Res. 2003, 60, 209-219). A lead compound of the series was selected for preclinical evaluation. This drug candidate, JNJ-2408068 (formerly R 17059 1, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. We herein describe the optimization program to develop compounds with improved properties in terms of tissue retention. We have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. We have investigated the replacement or the modification of this group, and we suggest that the pK(a) of this part of the molecules influences both the antiviral activity and the pharmacokinetic profile. We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.